Boostrix Purple Book BLA 125106

BLA number
125106
Proprietary names
Boostrix
Proper names
Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine, Adsorbed
Applicant
GlaxoSmithKline Biologicals
Center
CBER
First observed release
2020-08-01
Latest observed release
2026-06-01
Newest archive release
2026-06-01
FDA patent list
No patents listed in the captured FDA patent list; source updated 2025-06-11
Coverage
Present in newest release

Latest Known Product Presentations#

Product, Proprietary name, Proper name table
ProductProprietary nameProper nameLicense typeStrengthDosage formRoutePresentationMarketingLicensureApprovalPatent list provided
001BoostrixTetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine, Adsorbed351(a)2.5LF, 5LF, 2.5UG, 8UG UG/.5MLInjectionIntramuscularSingle-Dose VialRxLicensed2005-05-03
002BoostrixTetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine, Adsorbed351(a)2.5LF, 5LF, 2.5UG, 8UG UG/.5MLInjectionIntramuscularPre-Filled SyringeRxLicensed2005-05-03

Published Patent List#

No patents for this BLA were listed in the FDA Purple Book patent list captured from the source updated 2025-06-11.

Official Monthly Change Events#

Release, Event, Product table
ReleaseEventProductNameLicense typeStatusApplicant
2021-05-01U001Boostrix351(a)RxGlaxoSmithKline Biologicals
2021-05-01U002Boostrix351(a)RxGlaxoSmithKline Biologicals
2020-08-01R001Boostrix351(a)RxGlaxoSmithKline Biologicals
2020-08-01R002Boostrix351(a)RxGlaxoSmithKline Biologicals

Observed Product State History#

Release, Product, Name table
ReleaseProductNameLicense typeMarketingLicensureApproval
2020-08-01001Boostrix351(a)RxLicensed2005-05-03
2020-08-01002Boostrix351(a)RxLicensed2005-05-03